Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
48.405USD
-3.370-6.51%
Market hours 11/05, 13:37（ET）
4.68BMarket Cap
LossP/E TTM
CRISPR Therapeutics AG (CRSP) Stock Price Target & Forecast
Analyst Rating
Based on 23 analysts giving stock ratings to CRISPR Therapeutics AG in the past month.
Buy
4 Strong Buy
8 Buy
11 Hold
0 Sell
0 Strong Sell
Target Price
83.833USD+63.04%
CRSP Analyst Recommendation Trends
In the current month, CRSP has received 8 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the last month is 83.833.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
4
5
5
7
7
7
8
8
8
9
9
10
10
10
11
11
11
12
11
11
11
11
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
23
23
23
26
26
29
29
29
CRSP Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CRSP EPS is projected to reach -1.101 in FY2026Q4, following reported EPS of -1.152 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.22
-1.20
-1.04
-1.10
-0.90
Actual
-1.28
-0.94
-1.15
--
--
Surprise
-4.53%
+21.13%
-11.01%
--
--
FAQs
What is CRISPR Therapeutics AG's expected revenue for the next quarter?
CRISPR Therapeutics AG's expected revenue is 10.28M.
What is CRISPR Therapeutics AG's price target?
Analysts forecast that CRISPR Therapeutics AG's price target is USD 83.83, with the highest forecast at USD 291.00 and the lowest forecast at USD 44.00.
How have CRISPR Therapeutics AGCRSP's recent earnings per share performed?
The market expectation was USD -1.15, while CRISPR Therapeutics AGCRSP's earnings per share (EPS) for the previous quarter was USD -0.94. EPS for the next quarter is expected at USD -1.10.
What is the analyst rating for CRISPR Therapeutics AG?
Based on the ratings of CRISPR Therapeutics AG's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.